Earnings in 4d
APMD · NASDAQ · Biotechnology

Apnimed

Develops Oxnimbi, an oral therapy under FDA review for obstructive sleep apnea.

$30.30
After-hours close+0.57 (+1.92%)
At close$29.73(+3.52%)
DateEstimateReportedSurprise
Sep 2026−$0.49
Report dateEPS estEPSSurpriseRevenue estRevenueSurprise
Sep 2, 2026−$0.49